Published in Open Virol J on May 11, 2011
High transcript levels of vitamin D receptor are correlated with higher mRNA expression of human beta defensins and IL-10 in mucosa of HIV-1-exposed seronegative individuals. PLoS One (2013) 0.79
The oral mucosa immune environment and oral transmission of HIV/SIV. Immunol Rev (2013) 0.79
HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies. Pan Afr Med J (2015) 0.76
The Impact of Sex Work Interruption on Blood-Derived T Cells in Sex Workers from Nairobi, Kenya. AIDS Res Hum Retroviruses (2016) 0.75
High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals. Front Immunol (2017) 0.75
Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 11.11
The tripartite motif family identifies cell compartments. EMBO J (2001) 9.64
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol (2005) 5.24
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57
Mammalian defensins in immunity: more than just microbicidal. Trends Immunol (2002) 3.52
Defensins of vertebrate animals. Curr Opin Immunol (2002) 3.41
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A (1999) 3.21
Retracted Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science (2002) 2.81
HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol (2000) 2.69
HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS (2008) 2.67
Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 2.41
CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17
Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med (2007) 2.16
CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest (2001) 2.15
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol (2000) 2.13
Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol (2003) 1.96
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med (1997) 1.70
Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology (2006) 1.64
Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS (2008) 1.63
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology (2006) 1.59
CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol (2004) 1.56
The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol (2003) 1.49
Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest (2005) 1.47
Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis (2002) 1.42
Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie (2007) 1.40
Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology (2009) 1.37
The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect (2005) 1.35
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis (2007) 1.33
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol (2005) 1.30
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med (1997) 1.28
Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A (1999) 1.27
Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS (2009) 1.21
CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol (2003) 1.17
Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression. Am J Hum Genet (2006) 1.17
Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood (2000) 1.16
Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol (2006) 1.16
Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis (2001) 1.15
Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol (2001) 1.15
Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res (2008) 1.14
Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr (2005) 1.12
Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr (2006) 1.09
Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis (2000) 1.09
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS (2002) 1.09
Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression. PLoS One (2010) 1.08
Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS (2000) 1.07
Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS (2003) 1.06
Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. AIDS (2000) 1.05
Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine (2007) 1.03
Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr HIV Res (2007) 1.00
Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol (2000) 0.99
Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis (2007) 0.99
Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression. J Med Virol (2001) 0.98
Effect of intrauterine HIV-1 exposure on the frequency and function of uninfected newborns' dendritic cells. Clin Immunol (2008) 0.94
Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr (2004) 0.93
Frequency of CCR5 delta-32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medellin, Colombia. Mem Inst Oswaldo Cruz (2000) 0.91
Ribonucleases in HIV type 1 inhibition: effect of recombinant RNases on infection of primary T cells and immune activation-induced RNase gene and protein expression. AIDS Res Hum Retroviruses (2006) 0.88
Interferon-gamma and interleukin-10 production among HIV-1-infected and uninfected infants of HIV-1-infected mothers. Pediatr Res (2001) 0.87
New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia. AIDS (2004) 0.86
Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya. Clin Exp Immunol (2008) 0.86
The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS One (2007) 0.84
Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. AIDS (2010) 0.82
Apoptosis as a mechanism of natural resistance to HIV-1 infection in an exposed but uninfected population. J Clin Virol (2005) 0.81
[Soluble factors with inhibitory activity against type 1 Human Immunodeficiency Virus]. Biomedica (2006) 0.80
Human immunodeficiency virus (HIV) gag antigen-specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India. Clin Vaccine Immunol (2007) 0.80
Fetal-maternal HLA-A and -B discordance is associated with placental RNase expression and anti-HIV-1 activity. Curr HIV Res (2008) 0.76
Decreased density of the CCR5 receptor on the surface of CD4+ lymphocytes and monocytes/macrophages is associated with the CCR5-59653T transition in the promoter region. Folia Histochem Cytobiol (2002) 0.76
Human regulatory T cells are targets for human immunodeficiency Virus (HIV) infection, and their susceptibility differs depending on the HIV type 1 strain. J Virol (2009) 1.27
[Soluble factors with inhibitory activity against type 1 Human Immunodeficiency Virus]. Biomedica (2006) 0.80
[Interactions between human spermatozoids and human immunodeficiency virus]. Actas Urol Esp (2009) 0.78
Precursor Forms of Vitamin D Reduce HIV-1 Infection In Vitro. J Acquir Immune Defic Syndr (2016) 0.77
Differential expression of human beta defensins in placenta and detection of allelic variants in the DEFB1 gene from HIV-1 positive mothers. Biomedica (2011) 0.77
Fetal-maternal HLA-A and -B discordance is associated with placental RNase expression and anti-HIV-1 activity. Curr HIV Res (2008) 0.76
Short communication: Increased expression of secretory leukocyte protease inhibitor in oral mucosa of Colombian HIV type 1-exposed seronegative individuals. AIDS Res Hum Retroviruses (2012) 0.76
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort. Biomedica (2017) 0.75
[The human immunodeficiency virus type 1 and the developing central nervous system]. Biomedica (2005) 0.75
[Presence of circulating cytomegalic cells in HIV negative immunosuppressed individuals following cytomegalovirus infection]. Biomedica (2005) 0.75
[Effect of opportunistic infections on the frequency of leukocyte subpopulations from type-1 human immunodeficiency virus infected individuals]. Biomedica (2008) 0.75
Differential modulation of apoptosis and necrosis by antioxidants in immunosuppressed human lymphocytes. Toxicol Appl Pharmacol (2002) 0.75